Vaxcyte reports Q3 2026 results, loss per share of $1.99 beats consensus

Vaxcyte, Inc. reported its third quarter 2026 financial results on November 4, 2026, highlighting positive topline results from its OPUS-1 clinical trial, which management called a significant milestone for its pneumococcal conjugate vaccine franchise. The quarterly loss per share was $1.99, beating the consensus expectation of a $2.12 loss.

Detected & updated continuously · Source: Nebula